Global Generic Pharmaceuticals Market Report 2021: Market is Expected to Reach $331.54 Billion in 2025 at a CAGR of 7.8% with Long-term Forecast to 2030
December 09, 2021 05:13 ET
|
Research and Markets
Dublin, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The "Generic Pharmaceuticals Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. ...
Global Specialty Pharmaceutical Partnering Terms and Agreements Directory 2014-2021: Company A-Z, Stage of Development, Deal Type, and Therapy Focus
March 12, 2021 06:03 ET
|
Research and Markets
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Global Specialty Pharmaceutical Partnering Terms and Agreements 2014-2021" report has been added to ResearchAndMarkets.com's offering. The Global...
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights
May 14, 2018 07:00 ET
|
OptiNose, Inc.
Optinose confirms retail pharmacy availability of XHANCE commenced in early April Company reports more than 1,300 physicians have prescribed XHANCE through the Xperience program YARDLEY, Pa., May ...
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018
May 07, 2018 08:00 ET
|
OptiNose, Inc.
YARDLEY, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference
February 09, 2018 08:00 ET
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
October 17, 2017 16:01 ET
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by...
Optinose Announces Pricing of Initial Public Offering
October 12, 2017 21:17 ET
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 12, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by...
InnoPharma Inc. Announces Commercial Launch of Acamprosate Delayed-Release Tablets in the United States
August 15, 2013 08:00 ET
|
InnoPharma, Inc
PISCATAWAY, NJ, Aug. 15, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc.
today announced the launch of acamprosate calcium, 333 mg
delayed-release tablets (generic equivalent of
Campral®). ...